Overall, the results of this Mendelian randomization research indicated that IL-6R blockage may raise the risk of non-alcoholic fatty liver disease by blocking the IL-6 signaling pathway. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.